Advertisement

Therapy of Oral and Cutaneous Dryness Manifestations in Sjögren’s Syndrome

  • Robert I. Fox
  • Carla M. Fox
Chapter

Abstract

Sjögren’s syndrome (SjS) is characterized by dry eyes and dry mouth. This chapter will concentrate on the treatment of dry mouth and other mucosal surfaces, particularly skin and vaginal tissues.

Keywords

Dental Caries Salivary Flow Oral Candidiasis Salivary Flow Rate Vaginal Dryness 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

This chapter includes the contributions to patient care provided by the Scripps Oral Health Clinic (headed by Dr. John Weston) and our dedicated Oral Hygienists including Laurie Powell and Joanne Snyder who specialize in Sjögren’s syndrome, as well to our Dermatology associates particularly Drs. Alice Liu and Judith Kopersky, and our Gynecology and Urology associates particularly Drs. John Willems and John Naitoh.

References

  1. 1.
    Locker D, Clarke M, Payne B. Self-perceived oral health status, psychological well-being, and life satisfaction in an older adult population. J Dent Res. 2000;79:970.PubMedGoogle Scholar
  2. 2.
    Meijer JM, Meiners PM, Huddleston Slater JJR, Spijkervet FKL, Kallenberg CGM, Vissink A, et al. Health-related quality of life, employment and disability in patients with Sjogren’s syndrome. Rheumatology. 2009;48:1077.PubMedGoogle Scholar
  3. 3.
    Landi F, Russo A, Liperoti R, Cesari M, Barillaro C, Pahor M, et al. Anticholinergic drugs and physical function among frail elderly population. Clin Pharmacol Ther. 2006;81:235–41.PubMedGoogle Scholar
  4. 4.
    Fox RI. Sjogren’s syndrome. Lancet. 2005;366:321–31.PubMedGoogle Scholar
  5. 5.
    Bookman AAM, Shen H, Cook RJ, Bailey D, McComb RJ, Rutka JA, et al. Whole stimulated salivary flow: correlation with the pathology of inflammation and damage in minor salivary gland biopsy specimens from patients with primary Sjögren’s syndrome but not patients with sicca. Arthritis Rheum. 2011;63:2014–20.PubMedGoogle Scholar
  6. 6.
    Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. A unified theory of the role of the ocular surface in dry eye. Adv Exp Med Biol. 1998;438:643–51.PubMedGoogle Scholar
  7. 7.
    Stern ME, Gao J, Siemasko KF, Beuerman RW, Pflugfelder SC. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res. 2004;78:409–16.PubMedGoogle Scholar
  8. 8.
    Valls Sole J, Graus F, Font J, Pou A, Tolosa ES. Normal proprioceptive trigeminal afferents in patients with Sjogren’s syndrome and sensory neuronopathy. Ann Neurol. 1990;28:786–90.PubMedGoogle Scholar
  9. 9.
    Bergdahl M. Salivary flow and oral complaints in adult dental patients. Community Dent Oral Epidemiol. 2000;28:59–66.PubMedGoogle Scholar
  10. 10.
    Bergdahl M, Bergdahl J. Burning mouth syndrome: prevalence and associated factors. J Oral Pathol Med. 1999;28:350–4.PubMedGoogle Scholar
  11. 11.
    Femiano F, Scully C. Burning mouth syndrome (BMS): double blind controlled study of alpha-lipoic acid (thioctic acid) therapy. J Oral Pathol Med. 2002;31:267–9.PubMedGoogle Scholar
  12. 12.
    Grushka M, Ching V, Epstein J. Burning mouth syndrome. Adv Otorhinolaryngol. 2006;63:278–87.PubMedGoogle Scholar
  13. 13.
    Speciali J, Stuginski-Barbosa J. Burning mouth syndrome. Curr Pain Headache Rep. 2008;12:279–84.PubMedGoogle Scholar
  14. 14.
    Bergdahl M, Bergdahl J. Low unstimulated salivary flow and subjective oral dryness: association with medication, anxiety, depression, and stress. J Dent Res. 2000;79:1652.PubMedGoogle Scholar
  15. 15.
    Vriezekolk JE, Geenen R, Hartkamp A, Godaert GL, Bootsma H, Kruize AA, et al. Psycho­logical and somatic predictors of perceived and measured ocular dryness of patients with ­primary Sjogren’s syndrome. J Rheumatol. 2005;32:2351–5.PubMedGoogle Scholar
  16. 16.
    Strietzel F, Lafaurie G, Bautista M, Alajbeg I, Pejda S, Vuleti L, et al. Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter randomized trial. Arthritis Rheum. 2011;63:180–90. Epub 28 Dec 2010.PubMedGoogle Scholar
  17. 17.
    Strietzel F, MartÌn Granizo R, Fedele S, Lo Russo L, Mignogna M, Reichart P, et al. Electrostimulating device in the management of xerostomia. Oral Dis. 2007;13:206–13.PubMedGoogle Scholar
  18. 18.
    Fedele S, Wolff A, Strietzel F, Lopez R. Neuroelectrostimulation in treatment of hyposalivation and xerostomia in Sjogren’s syndrome: a salivary pacemaker. J Rheumatol. 2008;35:1489.PubMedGoogle Scholar
  19. 19.
    Fox RI, Liu AY. Sjogren’s syndrome in dermatology. Clin Dermatol. 2006;24:393–413.PubMedGoogle Scholar
  20. 20.
    Schiffman S, Miletic I. Effect of taste and smell on secretion rate of salivary IgA in elderly and young persons. J Nutr Health Aging. 1999;3:158–64.PubMedGoogle Scholar
  21. 21.
    Daniels T. Sjogren’s syndrome: clinical spectrum and current diagnostic controversies. Adv Dent Res. 1996;10:3.PubMedGoogle Scholar
  22. 22.
    Al-Hashimi I. The management of Sjogren’s syndrome in dental practice. J Am Dent Assoc. 2001;132:1409–17; quiz 60–1.PubMedGoogle Scholar
  23. 23.
    Al-Hashimi I. Sjogren’s syndrome: diagnosis and management. Womens Health. 2007;3:107–22.Google Scholar
  24. 24.
    Nagy K, Urban E, Fazekas O, Thurzo L, Nagy E. Controlled study of lactoperoxidase gel on oral flora and saliva in irradiated patients with oral cancer. J Craniofac Surg. 2007;18:1157–64.PubMedGoogle Scholar
  25. 25.
    Warde P, Kroll B, O’Sullivan B, Aslanidis J, Tew-George E, Waldron J, et al. A phase II study of Biotene in the treatment of postradiation xerostomia in patients with head and neck cancer. Support Care Cancer. 2000;8:203–8.PubMedGoogle Scholar
  26. 26.
    Temmel A, Quint C, Schickinger-Fischer B, Hummel T. Taste function in xerostomia before and after treatment with a saliva substitute containing carboxymethylcellulose. J Otolaryngol. 2005;34:116.PubMedGoogle Scholar
  27. 27.
    Schubert MM, Peterson DE, Lloid ME. Oral complications. In: Thomas ED, Blume KG, Forman SJ, editors. Hematopoietic cell transplantation. Oxford: Blackwell Science; 1999. p. 751–63.Google Scholar
  28. 28.
    MacFarlane T, Mason D. Changes in the oral flora in Sjogren’s syndrome. J Clin Pathol. 1974;27:416.PubMedGoogle Scholar
  29. 29.
    Ayars GH, Altman LC, Fretwell MD. Effect of decreased salivation and pH on the adherence of Klebsiella species to human buccal epithelial cells. Infect Immun. 1982;38:179.PubMedGoogle Scholar
  30. 30.
    Zero DT. Etiology of dental erosion – extrinsic factors. Eur J Oral Sci. 1996;104:162–77.PubMedGoogle Scholar
  31. 31.
    Larsen M, Nyvad B. Enamel erosion by some soft drinks and orange juices relative to their pH, buffering effect and contents of calcium phosphate. Caries Res. 2000;33:81–7.Google Scholar
  32. 32.
    Newbrun E. Current treatment modalities of oral problems of patients with Sjogren’s syndrome: caries prevention. Adv Dent Res. 1996;10:29–34.PubMedGoogle Scholar
  33. 33.
    Paster B, Boches S, Galvin J, Ericson R, Lau C, Levanos V, et al. Bacterial diversity in human subgingival plaque. J Bacteriol. 2001;183:3770.PubMedGoogle Scholar
  34. 34.
    Daniels T, Fox P. Salivary and oral components of Sjogren’s syndrome. Rheum Dis Clin North Am. 1992;18:571.PubMedGoogle Scholar
  35. 35.
    Astor FC, Hanft KL, Ciocon JO. Xerostomia: a prevalent condition in the elderly. Ear Nose Throat J. 1999;78:476–9.PubMedGoogle Scholar
  36. 36.
    Pedersen A, Bardow A, Nauntofte B. Salivary changes and dental caries as potential oral markers of autoimmune salivary gland dysfunction in primary Sjogren’s syndrome. BMC Clin Pathol. 2005;5:4.PubMedGoogle Scholar
  37. 37.
    Christensen L, Petersen P, Thorn J, SchiØdt M. Dental caries and dental health behavior of patients with primary Sjogren’s syndrome. Acta Odontol Scand. 2001;59:116–20.PubMedGoogle Scholar
  38. 38.
    Castillo JL, Milgrom P. Fluoride release from varnishes in two in vitro protocols. J Am Dent Assoc. 2004;135:1696–9.PubMedGoogle Scholar
  39. 39.
    Castillo JL, Milgrom P, Kharasch E, Izutsu K, Fey M. Evaluation of fluoride release from commercially available fluoride varnishes. J Am Dent Assoc. 2001;132:1389–92; quiz 459–60.PubMedGoogle Scholar
  40. 40.
    Daniels TE, Fox PC. Salivary and oral components of Sjogren’s syndrome. Rheum Dis Clin North Am. 1992;18:571–89.PubMedGoogle Scholar
  41. 41.
    Mann J, Karniel C, Triol CW, Sintes JL, Garcia L, Petrone ME, et al. Comparison of the clinical anticaries efficacy of a 1500 NaF silica-based dentifrice containing triclosan and a copolymer to a 1500 NaF silica-based dentifrice without those additional agents: a study on adults in Israel. J Clin Dent. 1996;7:90–5.PubMedGoogle Scholar
  42. 42.
    Pfarrer AM, White DJ, Featherstone JD. Anticaries profile qualification of an improved whitening dentifrice. J Clin Dent. 2001;12:30–3.PubMedGoogle Scholar
  43. 43.
    Banting DW, Papas A, Clark DC, Proskin HM, Schultz M, Perry R. The effectiveness of 10% chlorhexidine varnish treatment on dental caries incidence in adults with dry mouth. Gerodontology. 2000;17:67–76.PubMedGoogle Scholar
  44. 44.
    Epstein JB, Loh R, Stevenson-Moore P, McBride BC, Spinelli J. Chlorhexidine rinse in ­prevention of dental caries in patients following radiation therapy. Oral Surg Oral Med Oral Pathol. 1989;68:401–5.PubMedGoogle Scholar
  45. 45.
    Johansson G, Andersson G, Edwardsson S, Bjorn AL, Manthorpe R, Attstrom R. Effects of mouthrinses with linseed extract Salinum without/with chlorhexidine on oral conditions in patients with Sjogren’s syndrome. A double-blind crossover investigation. Gerodontology. 2001;18:87–94.PubMedGoogle Scholar
  46. 46.
    Ship JA, McCutcheon JA, Spivakovsky S, Kerr AR. Safety and effectiveness of topical dry mouth products containing olive oil, betaine, and xylitol in reducing xerostomia for polypharmacy-induced dry mouth. J Oral Rehabil. 2007;34:724–32.PubMedGoogle Scholar
  47. 47.
    Sintes JL, Escalante C, Stewart B, McCool JJ, Garcia L, Volpe AR, et al. Enhanced anticaries efficacy of a 0.243% sodium fluoride/10% xylitol/silica dentifrice: 3-year clinical results. Am J Dent. 1995;8:231–5.PubMedGoogle Scholar
  48. 48.
    Isidor F, Brondum K, Hansen HJ, Jensen J, Sindet-Pedersen S. Outcome of treatment with implant-retained dental prostheses in patients with Sjogren syndrome. Int J Oral Maxillofac Implants. 1999;14:736–43.PubMedGoogle Scholar
  49. 49.
    Payne AG, Lownie JF, Van Der Linden WJ. Implant-supported prostheses in patients with Sjogren’s syndrome: a clinical report on three patients. Int J Oral Maxillofac Implants. 1997;12:679–85.PubMedGoogle Scholar
  50. 50.
    Ramos-Casals M, Brito-Zerón P. New approaches in Sjögren’s syndrome therapy. Expert Rev Clin Immunol. 2007;3:195–204.Google Scholar
  51. 51.
    Peluso G, De Santis M, Inzitari R, Fanali C, Cabras T, Messana I, et al. Proteomic study of salivary peptides and proteins in patients with Sjogren’s syndrome before and after pilocarpine treatment. Arthritis Rheum. 2007;56:2216–22.PubMedGoogle Scholar
  52. 52.
    Wu CH, Hsieh SC, Lee KL, Li KJ, Lu MC, Yu CL. Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren’s syndrome in Taiwan-A double-blind, placebo-­controlled trial. J Formos Med Assoc. 2006;105:796–803.PubMedGoogle Scholar
  53. 53.
    Bhamra J, Wong J, Gohill J. Oral pilocarpine for the treatment of keratoconjunctivitis sicca with central corneal irregularity. J Cataract Refract Surg. 2003;29:2236–8.PubMedGoogle Scholar
  54. 54.
    Vivino FB. The treatment of Sjogren’s syndrome patients with pilocarpine-tablets. Scand J Rheumatol Suppl. 2001;115:1–9; discussion 9−13.PubMedGoogle Scholar
  55. 55.
    Fox RI, Konttinen Y, Fisher A. Use of muscarinic agonists in the treatment of Sjogren’s syndrome. Clin Immunol. 2001;101:249–63.PubMedGoogle Scholar
  56. 56.
    al-Hashimi I, Taylor SE. A new medication for treatment of dry mouth in Sjogren’s syndrome. Tex Dent J. 2001;118:262–6.PubMedGoogle Scholar
  57. 57.
    Fox RI, Stern M, Michelson P. Update in Sjogren syndrome. Curr Opin Rheumatol. 2000;12:391–8.PubMedGoogle Scholar
  58. 58.
    Gibson J, Halliday JA, Ewert K, Robertson S. A controlled release pilocarpine buccal insert in the treatment of Sjögren’s syndrome. Br Dent J. 2007;202:E17.PubMedGoogle Scholar
  59. 59.
    Yeoman C. A controlled release buccal insert. Br Dent J. 2007;202:404–5.Google Scholar
  60. 60.
    Leung KCM, McMillan AS, Wong MCM, Leung WK, Mok MY, Lau CS. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren’s syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study. Clin Rheumatol. 2008;27:429–36.PubMedGoogle Scholar
  61. 61.
    Yamada H, Nakagawa Y, Wakamatsu E, Sumida T, Yamachika S, Nomura Y, et al. Efficacy prediction of cevimeline in patients with Sjögren’s syndrome. Clin Rheumatol. 2007;26:1320–7.PubMedGoogle Scholar
  62. 62.
    Yamada H, Nakagawa Y, Wakamatsu E, Sumida T, Yamachika S, Nomura Y, et al. Efficacy prediction of cevimeline in patients with Sjogren’s syndrome. Clin Rheumatol. 2007;26:1320–7.PubMedGoogle Scholar
  63. 63.
    Suzuki K, Matsumoto M, Nakashima M, Takada K, Nakanishi T, Okada M, et al. Effect of cevimeline on salivary components in patients with Sjogren syndrome. Pharmacology. 2005;74:100–5.PubMedGoogle Scholar
  64. 64.
    Takagi Y, Kimura Y, Nakamura T. Cevimeline gargle for the treatment of xerostomia in patients with Sjogren’s syndrome. Ann Rheum Dis. 2004;63:749.PubMedGoogle Scholar
  65. 65.
    Mavragani CP, Moutsopoulos HM. Conventional therapy of Sjogren’s syndrome. Clin Rev Allergy Immunol. 2007;32:284–91.PubMedGoogle Scholar
  66. 66.
    Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P. A double-blind, randomized, placebo-controlled study of cevimeline in Sjoegren’s syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. 2002;46:748–54.PubMedGoogle Scholar
  67. 67.
    Epstein JB, Burchell JL, Emerton S, Le ND, Silverman S. A clinical trial of bethanechol in patients with xerostomia after radiation therapy: a pilot study. Oral Surg Oral Med Oral Pathol. 1994;77:610–4.PubMedGoogle Scholar
  68. 68.
    Llorente I, Lizcano F, Alvarez R, Diez N, Sopena M, Gil MJ, et al. Cholinergic modulation of spontaneous hypothalamic-pituitary-adrenal activity and its circadian variation in man. J Clin Endocrinol Metab. 1996;81:2902–7.PubMedGoogle Scholar
  69. 69.
    Bhalla R, Swedler WI, Lazarevic MB, Ajmani HS, Skosey JL. Myasthenia gravis and scleroderma. J Rheumatol. 1993;20:1409–10.PubMedGoogle Scholar
  70. 70.
    Bohuslavizki KH, Brenner W, Klutmann S, Hubner RH, Lassmann S, Feyerabend B, et al. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy. J Nucl Med. 1998;39:1237.PubMedGoogle Scholar
  71. 71.
    Olver IN. Xerostomia: a common adverse effect of drugs and radiation. Aust Prescriber. 2006;29:97–8.Google Scholar
  72. 72.
    Misawa M, Ohmori S, Yanaura S. Effects of bromhexine on the secretions of saliva and tears. J Pharmacol. 1985;39:241–50.Google Scholar
  73. 73.
    Avisar R, Savir H, Machtey I, Ovaknin L, Shaked P, Menache R, et al. Clinical trial of bromhexine in Sjogren’s syndrome. Ann Ophthalmol. 1981;13:971.PubMedGoogle Scholar
  74. 74.
    Frost-Larsen K, Isager H, Manthorpe R. Sjogren’s syndrome treated with bromhexine: a randomised clinical study. Br Med J. 1978;1:1579.PubMedGoogle Scholar
  75. 75.
    Jayaram S, Desai A. Efficacy and safety of Ascoril expectorant and other cough formula in the treatment of cough management in paediatric and adult patients – a randomised double-blind comparative trial. J Indian Med Assoc. 2000;98:68.PubMedGoogle Scholar
  76. 76.
    Barnard DL. Interferon-alpha. Amarillo Biosciences. Curr Opin Investig Drugs. 2002;3:693–7.PubMedGoogle Scholar
  77. 77.
    Khurshudian AV. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjogren’s syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;95:38–44.PubMedGoogle Scholar
  78. 78.
    Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of primary Sjogren’s syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum. 2003;49:585–93.PubMedGoogle Scholar
  79. 79.
    Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjogren’s syndrome. J Interferon Cytokine Res. 1998;18:255–62.PubMedGoogle Scholar
  80. 80.
    Blom M, Dawidson I, Angmar-MÂnsson B. The effect of acupuncture on salivary flow rates in patients with xerostomia* 1. Oral Surg Oral Med Oral Pathol. 1992;73:293–8.PubMedGoogle Scholar
  81. 81.
    Dawidson I, Angmar-Mânsson B, Blom M, Theodorsson E, Lundeberg T. Sensory stimulation (acupuncture) increases the release of calcitonin gene-related peptide in the saliva of xerostomia sufferers* 1. Neuropeptides. 1999;33:244–50.PubMedGoogle Scholar
  82. 82.
    Fox PC, Cummins MJ, Cummins JM. Use of orally administered anhydrous crystalline maltose for relief of dry mouth. J Altern Complement Med. 2001;7:33–43.PubMedGoogle Scholar
  83. 83.
    Epstein J, Decoteau W, Wilkinson A. Effect of sialor in treatment of xerostomia in Sjogren’s syndrome. Oral Surg Oral Med Oral Pathol. 1983;56:495–9.PubMedGoogle Scholar
  84. 84.
    Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjogren’s syndrome: a pilot study. Arthritis Rheum. 2001;44:2371–5.PubMedGoogle Scholar
  85. 85.
    Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Inefficacy of ­infliximab in primary Sjogren’s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren’s Syndrome (TRIPSjS). Arthritis Rheum. 2004;50:1270–6.PubMedGoogle Scholar
  86. 86.
    Moutsopoulos NM, Katsifis GE, Angelov N, Leakan RA, Sankar V, Pillemer S, et al. Lack of efficacy of etanercept in Sjogren’s syndrome correlates with failed suppression of TNF alpha and systemic immune activation. Ann Rheum Dis. 2008;67:1437–43.PubMedGoogle Scholar
  87. 87.
    Zandbelt MM, de Wilde P, van Damme P, Hoyng CB, van de Putte L, van den Hoogen F. Etanercept in the treatment of patients with primary Sjogren’s syndrome: a pilot study. J Rheumatol. 2004;31:96–101.PubMedGoogle Scholar
  88. 88.
    Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, et al. Etanercept in Sjogren’s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50:2240–5.PubMedGoogle Scholar
  89. 89.
    Zapata LF, Agudelo LM, Paulo JD, Pineda R. Sjogren keratoconjunctivitis sicca treated with rituximab. Cornea. 2007;26:886–7.PubMedGoogle Scholar
  90. 90.
    Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, et al. Improvement of Sjogren’s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 2007;57:310–7.PubMedGoogle Scholar
  91. 91.
    Pijpe J, van Imhoff GW, Vissink A, van der Wal JE, Kluin PM, Spijkervet FK, et al. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren’s syndrome and associated MALT lymphoma. Ann Rheum Dis. 2005;64:958–60.PubMedGoogle Scholar
  92. 92.
    Meijer JM, Pijpe J, Vissink A, Kallenberg C, Bootsma H. Treatment of primary Sjogren’s syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis. 2009;68:284.PubMedGoogle Scholar
  93. 93.
    Meijer JM, Meiners P, Vissink A, Spijkervet F, Abdulahad W, Kamminga N, et al. Effectiveness of rituximab treatment in primary Sjogren’s syndrome: a randomized, double blind, placebo controlled trial. Arthritis Rheum. 2010;62:960–8.PubMedGoogle Scholar
  94. 94.
    Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren’s syndrome: an open-label phase I/II study. Arthritis Res Ther. 2006;8:R129.PubMedGoogle Scholar
  95. 95.
    d’Arbonneau F, Pers JO, Devauchelle V, Pennec Y, Saraux A, Youinou P. BAFF-induced changes in B cell antigen receptor-containing lipid rafts in Sjogren’s syndrome. Arthritis Rheum. 2006;54:115–26.PubMedGoogle Scholar
  96. 96.
    Pers JO, d’Arbonneau F, Devauchelle-Pensec V, Saraux A, Pennec YL, Youinou P. Is periodontal disease mediated by salivary baff in Sjogren’s syndrome? Arthritis Rheum. 2005;52:2411–4.PubMedGoogle Scholar
  97. 97.
    Rhodus NL, Michalowicz BS. Periodontal status and sulcular Candida albicans colonization in patients with primary Sjogren’s syndrome. Quintessence Int. 2005;36:228–33.PubMedGoogle Scholar
  98. 98.
    Azuma T, Takei M, Yoshikawa T, Nagasugi Y, Kato M, Otsuka M, et al. Identification of candidate genes for Sjogren’s syndrome using MRL/lpr mouse model of Sjogren’s syndrome and cDNA microarray analysis. Immunol Lett. 2002;81:171–6.PubMedGoogle Scholar
  99. 99.
    Rhodus NL, Bloomquist C, Liljemark W, Bereuter J. Prevalence, density, and manifestations of oral Candida albicans in patients with Sjogren’s syndrome. J Otolaryngol. 1997;26:300–5.PubMedGoogle Scholar
  100. 100.
    Tapper-Jones L, Aldred M, Walker D. Prevalence and intraoral distribution of Candida albicans in Sjogren’s syndrome. J Clin Pathol. 1980;33:282.PubMedGoogle Scholar
  101. 101.
    Samaranayake YH, Samaranayake LP, Wu PC, So M. The antifungal effect of lactoferrin and lysozyme on Candida krusei and Candida albicans. APMIS. 1997;105:875–83.PubMedGoogle Scholar
  102. 102.
    Samaranayake L, MacFarlane T. Factors affecting the in-vitro adherence of the fungal oral pathogen Candida albicans to epithelial cells of human origin. Arch Oral Biol. 1982;27:869–73.PubMedGoogle Scholar
  103. 103.
    Samarkos M, Moutsopoulos HM. Recent advances in the management of ocular ­complications of Sjogren’s syndrome. Curr Allergy Asthma Rep. 2005;5:327–32.PubMedGoogle Scholar
  104. 104.
    Tauber J, Davitt WF, Bokosky JE, Nichols KK, Yerxa BR, Schaberg AE, et al. ­Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea. 2004;23:784–92.PubMedGoogle Scholar
  105. 105.
    Profita M, Sala A, Riccobono L, Pace E, PaternÚ A, Zarini S, et al. 15 (S)-HETE modulates LTB4 production and neutrophil chemotaxis in chronic bronchitis. Am J Physiol Cell Physiol. 2000;279:C1249.PubMedGoogle Scholar
  106. 106.
    Oka H, Nakano H, Kimata T, Matsuda T, Ozaki S. Effect of rebamipide for the treatment of xerostomia in patients with Sjogren’s syndrome. Progr Med. 2004;24:205–10.Google Scholar
  107. 107.
    Ichikawa T, Ishihara K, Hayashida H, Hiruma H, Saigenji K, Hotta K. Effects of ecabet sodium, a novel gastroprotective agent, on mucin metabolism in rat gastric mucosa. Dig Dis Sci. 2000;45:606–13.PubMedGoogle Scholar
  108. 108.
    Nakamura M, Endo K, Nakata K, Hamano T. Gefarnate stimulates secretion of mucin-like glycoproteins by corneal epithelium in vitro and protects corneal epithelium from desiccation in vivo. Exp Eye Res. 1997;65:569–74.PubMedGoogle Scholar
  109. 109.
    Carsons S. A review and update of Sjogren’s syndrome: manifestations, diagnosis, and treatment. Am J Manag Care. 2001;7:433–43.Google Scholar
  110. 110.
    Graziottin A. Clinical approach to dyspareunia. J Sex Marital Ther. 2001;27:489–501.PubMedGoogle Scholar
  111. 111.
    Fleming Cole N, Toy EC, Baker B. Sjogren’s syndrome. Prim Care Update Ob Gyns. 2001;8:48–51.PubMedGoogle Scholar
  112. 112.
    Johnson EO, Skopouli FN, Moutsopoulos HM. Neuroendocrine manifestations in Sjogren’s syndrome [In Process Citation]. Rheum Dis Clin North Am. 2000;26:927–49.PubMedGoogle Scholar
  113. 113.
    Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JAE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332:1589–93.PubMedGoogle Scholar
  114. 114.
    Buyon JP, Kalunian KC, Skovron ML, Petri M, Lahita R, Merrill J, et al. Can women with systemic lupus erythematosus safely use exogenous estrogens? JCR: J Clin Rheumatol. 1995;1:205.PubMedGoogle Scholar
  115. 115.
    Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005;142:953–62.PubMedGoogle Scholar
  116. 116.
    Petri M. Long-term outcomes in lupus. Am J Manag Care. 2001;7:S480–5.PubMedGoogle Scholar
  117. 117.
    Sullivan DA, Belanger A, Cermak JM, Berube R, Papas AS, Sullivan RM, et al. Are women with Sjögren’s syndrome androgen-deficient? J Rheumatol. 2003;30:2413–9.PubMedGoogle Scholar
  118. 118.
    Petri MA, Lahita RG, van Vollenhoven RF, Merrill J, Schiff M, Ginzler EM, et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus. Arthritis Rheum. 2002;46:1820–9.PubMedGoogle Scholar
  119. 119.
    Petri M. Exogenous estrogen in systemic lupus erythematosus: oral contraceptives and ­hormone replacement therapy. Lupus. 2001;10:222–6.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2011

Authors and Affiliations

  1. 1.Rheumatology ClinicScripps Memorial Hospital and Research FoundationLa JollaUSA

Personalised recommendations